Research Category
Growth Hormone Secretagogue Research
Compounds studied for their action on growth hormone release pathways, primarily the GHRH receptor and the ghrelin receptor in pituitary cell models. Every lot ships with batch documentation.
4 products
CJC-1295 no DAC + Ipamorelin
This set includes one CJC-1295 no DAC compound and one Ipamorelin compound. Each compound is packaged separately and is not pre-mixed.
A GHRH-analog and selective-secretagogue pairing, studied together for a larger combined growth-hormone pulse than either compound produces alone.
Scientific profile
- CJC-1295 no DAC
- CAS —
- Ipamorelin
- CAS 170851-70-4
About growth hormone secretagogue research
Ipamorelin is a selective ghrelin receptor agonist with a completed clinical trial history. CJC-1295 without DAC is a GHRH analog studied for pulsatile release patterns. Tesamorelin is the most clinically documented GHRH analog in the class. The receptor selectivity differences between these compounds are the main subject of the comparative literature.
What to verify before ordering
Combination products list each peptide separately on the COA with individual identity and purity results. Single-compound lots carry the standard three-method documentation. Storage reference data is on each product page.
Compounds in this category
Ipamorelin, CJC-1295 no DAC, the CJC-1295 + Ipamorelin combination, and Tesamorelin. The Insights library includes a research profile of Ipamorelin's completed trial program, a comparison of CJC-1295 with and without DAC, and a profile of Tesamorelin's drug-label history.